Bladder Tumors Invading the Lamina propria (Stage A/Tl): Influence of Endovesical Bacillus Calmette-Guérin Therapy on Recurrence and Progression

Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette‐Guérin (Danish 1331 strain)

“…Thus, the net benefit of BCG therapy is preservation of the bladder in 88% of patients. Similar results were reported by others with different strains of BCG [3–8]. The T1G3 recurrences after BCG were treated with either a second course of BCG in a few or radical cystectomy in most patients.…”

“…Historically, early cystectomy for T1G3 tumours had yielded good results but currently the emphasis is on bladder preservation. Various authors have reported success and failure in the management of T1G3 tumours using various strains of intravesical BCG in an adjuvant setting [3–23]. We herein report our experience of managing 69 patients with T1G3 bladder tumours using endovesical BCG (Danish 1331 strain).…”

The Effect of Postoperative Intravesical BCG and Mitomycin C Therapy on Recurrence of Non-Muscle Invasive Bladder Cancer

“…Boccon-Gibod et al followed 47 T1 patients, who received BCG treatment between one or three sessions for 14 to 60 months. In BCG group, they found 36% recurrence and 21% progression risk, whereas in the control group, there was 90% recurrence and 34% progression risk [12]. Pansadoro et al reported a study which they applied at least 6 weeks of BCG treatment to 50 patients with high grade T1 disease.…”